ArticleAmerican journal of cancer research2025
Preoperative red blood cell transfusion improves treatment response and survival in patients with locally advanced esophageal cancer and iron deficiency anemia.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLocally advanced esophageal cancer presents significant treatment challenges, with iron deficiency anemia (IDA) potentially hindering the efficacy of neoadjuvant chemotherapy. This study aimed to evaluate the effect of preoperative red blood cell transfusion on tumor progression and chemotherapy response in patients with IDA.
methodsA retrospective cohort study was conducted at Shaanxi Provincial Cancer Hospital, involving 228 patients with locally advanced esophageal cancer and IDA, from August 2015 to August 2021. Patients were divided into two groups: 106 patients received preoperative red blood cell transfusions, and 122 did not. All patients underwent a standardized chemotherapy regimen followed by surgery. Hematological, immunological, and biochemical parameters, as well as chemotherapy-related adverse events, and survival outcomes were analyzed.
resultsPreoperative transfusion significantly increased hemoglobin (Hb) levels (P < 0.05), enhanced immunological profiles (e.g., NK/T cell activity; P < 0.05), and reduced systemic inflammation (e.g., CRP; P < 0.05) after chemotherapy and operation. Overall survival and progression-free survival were notably better in the transfusion group (P = 0.002 and P = 0.012, respectively).
conclusionPreoperative red blood cell transfusion improves hematological and immunological parameters and enhances survival outcomes in patients with locally advanced esophageal cancer and IDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.